ReviewFoods (Basel, Switzerland)2026
Food-Derived Multi-Target Antihypertensive Peptides: Sources, Mechanisms and AI-Driven Strategies.
Review in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hypertension is a major global public health challenge. Traditional antihypertensive drugs often cause side effects, which has prompted growing interest in natural antihypertensive agents. However, most existing antihypertensive peptides target single pathways, thereby constraining their effectiveness against hypertension's complex mechanisms. In contrast, multi-target peptides modulate complex hypertension-related networks, offering enhanced blood pressure control and reduced resistance risks. This narrative review comprehensively summarizes the latest research progress on multi-target antihypertensive peptides, including their main food sources (animal, plant, and microorganism sources) and bioactive mechanisms. In addition, this review also describes the process of artificial intelligence (AI) and network pharmacology-driven multi-target antihypertensive peptide screening, and summarizes the machine learning (ML) models and activity prediction websites that have been applied to antihypertensive peptide screening. Finally, this review explores the challenges and future directions in multi-target antihypertensive peptide research, thereby providing a theoretical basis for the development of novel multi-target antihypertensive peptides.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.